Updated: Vertex makes money from gene-edited therapy Casgevy
Vertex said it made $2 million in revenue from the first patient who received Casgevy, its therapy for sickle cell disease and beta thalassemia. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
